Oncternal Therapeutics, Inc. (ONCT)
NASDAQ: ONCT · IEX Real-Time Price · USD
7.00
-0.08 (-1.13%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Oncternal Therapeutics Employees
As of December 31, 2023, Oncternal Therapeutics had 30 total employees, including 27 full-time and 3 part-time employees. The number of employees decreased by 3 or -9.09% compared to the previous year.
Employees
30
Change (1Y)
-3
Growth (1Y)
-9.09%
Revenue / Employee
$38,367
Profits / Employee
-$1,212,667
Market Cap
20.72M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Singular Genomics Systems | 255 |
Cosmos Health | 102 |
Cumberland Pharmaceuticals | 91 |
BiomX | 71 |
Jaguar Health | 49 |
American Shared Hospital Services | 31 |
AIM ImmunoTech | 28 |
Iterum Therapeutics | 14 |
ONCT News
- 10 days ago - Oncternal Therapeutics to Present in JonesTrading Healthcare Summit - GlobeNewsWire
- 7 weeks ago - Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer - GlobeNewsWire
- 2 months ago - Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - Oncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer - GlobeNewsWire
- 4 months ago - Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer - GlobeNewsWire
- 4 months ago - Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire